This article was originally published in Start Up
Anti-angiogenesis as a treatment for cancer was hardly a new concept, even in 1998 when a New York Times article first put Judah Folkman's work on the public map. Although the hype has died away, the industrial machine of anti-angiogenesis has continued to roll on--as indicated by the start-up activity we describe in the following profiles.
You may also be interested in...
Pivotal BioSciences Inc.
With two product candidates in its portfolio--contortrostatin (an anti-angiogenic agent purified from snake venom), and a proprietary low-dose version of interleukin-2--Pivotal BioSciences hopes to be a catalyst for other university-based researchers in the Los Angeles area to develop their discoveries under its corporate umbrella.
Oncology Sciences Corp.
Founded in close affiliation with Denver's AMC Cancer Research Center, Oncology Sciences Corp. is taking a natural approach to fighting prostate cancer. It is focusing on preclinical development of an endogenous angiogenesis inhibitor as well as other natural substances that work through anti-angiogenic and additional mechanisms.
Cell Matrix Inc.
The enthusiasm of the founders of Cell Matrix, which was founded in late 1999 to pursue its own anti-angiogenesis approach to cancer, hasn't been dampened by the failures of its forebears. They believe the company has what competitors lack: a family of antibodies that is selective for angiogenesis.